首页> 外文OA文献 >Distinct outcomes of chloride diarrhoea in two siblings with identical genetic background of the disease: implications for early diagnosis and treatment
【2h】

Distinct outcomes of chloride diarrhoea in two siblings with identical genetic background of the disease: implications for early diagnosis and treatment

机译:具有相同遗传背景的两个兄弟姐妹的氯化物腹泻的不同结果:对早期诊断和治疗的意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND—Congenital chloride diarrhoea (CLD, OMIM 214700) is a serious inherited defect of intestinal electrolyte absorption transmitted in an autosomal recessive fashion. The major clinical manifestation is diarrhoea with high chloride content which can be balanced by substitution. The molecular pathology involves an epithelial Cl /HCO3 exchanger protein, encoded by the solute carrier family 26, member 3 gene (SLC26A3), previously known as CLD or DRA (downregulated in adenomas). To date, almost 30 different mutations in the SLC26A3 gene have been identified throughout the world. No clear genotype-phenotype correlation has been established.
PATIENTS/METHODS—Two siblings presenting with CLD were studied for disease history, supplementation, or other treatments, and for mutations in the SLC26A3 gene.
RESULTS—Mutation analysis revealed a homozygous I544N mutation in both patients. However, despite the uniform genetic background of CLD in this family, the clinical picture and outcome of the disease were remarkably different between siblings. The older sibling had a late diagnosis and chronic course of the disease whereas the younger one, who was diagnosed soon after birth and immediately received supplementation therapy, grows and develops normally.
CONCLUSION—Time of diagnosis, substitution therapy, compliance, and compensatory mechanisms are more important modulators of the clinical picture of CLD than the type of mutation in the SLC26A3 gene.


Keywords: chloride diarrhoea; SLC26A3 gene;
机译:背景—先天性氯化物腹泻(CLD,OMIM 214700)是一种以常染色体隐性方式传播的严重的遗传性肠道电解质吸收缺陷。主要临床表现是腹泻,氯化物含量高,可以通过替代来平衡。分子病理学涉及由溶质载体家族26成员3基因(SLC26A3)编码的上皮Cl / HCO3交换蛋白,以前称为CLD或DRA(在腺瘤中下调)。迄今为止,全世界已经鉴定出SLC26A3基因中近30种不同的突变。尚无明确的基因型与表型相关性。患者/方法-研究了两个患有CLD的兄弟姐妹的病史,补充或其他治疗方法,以及SLC26A3基因的突变。结果—突变分析显示两名患者均发生I544N纯合突变。然而,尽管该家族中CLD具有统一的遗传背景,但兄弟姐妹之间的临床表现和疾病结局却明显不同。年龄较大的兄弟姐妹诊断较晚,患有慢性病,而年龄较小的兄弟姐妹出生后不久就被诊断出并立即接受补充疗法,能够正常生长和发育。结论—诊断时间,替代疗法,依从性和补偿机制是CLD临床表现的重要调节剂,而不是SLC26A3基因突变的类型。关键字:氯化物腹泻; SLC26A3基因;

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号